HIMS stock dropped 34% after collaboration end with Novo Nordisk over concerns of misconduct.

From Zacks Investment Research: 2025-06-24 17:48:00

Hims (HIMS) stock plunged 34% after Novo Nordisk ended collaboration over concerns of “illegal mass compounding and deceptive marketing.” CEO denies allegations, accusing Novo Nordisk of pressuring them to promote Wegovy over patient needs. Stock fell below 50-day moving average at $47.45, with 200-day at $33.46. Technical analyst Dave Bartosiak highlights moving averages, support/resistance levels, chart patterns, and volume analysis to aid investors in navigating market trends. While technical analysis is valuable, consider fundamental analysis and market sentiment before making investment decisions.



Read more at Zacks Investment Research: Can Hims Recover after Novo Nordisk Diss? – June 24, 2025